Oragenics Inc
$ 0.71
9.02%
24 Feb - close price
- Market Cap 2,697,700 USD
- Current Price $ 0.71
- High / Low $ 0.74 / 0.67
- Stock P/E 0.01
- Book Value 2.38
- EPS 48.21
- Next Earning Report 2026-03-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.71 %
- ROE -1.69 %
- 52 Week High 9.60
- 52 Week Low 0.61
About
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company is headquartered in Tampa, Florida.
Analyst Target Price
$2.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-08 | 2025-05-09 | 2025-03-27 | 2024-11-07 | 2024-08-09 | 2024-05-15 | 2024-03-29 | 2023-11-09 | 2023-08-11 | 2023-04-17 | 2023-03-27 |
| Reported EPS | -1.96 | -3.1 | -3.65 | -0.2664 | -0.3773 | -0.509 | -0.701 | -4.1378 | -0.8543 | -1.5066 | -0.15 | -1.1101 |
| Estimated EPS | 0 | 0 | None | None | None | None | None | None | None | -3 | -2.4 | -2.4 |
| Surprise | -1.96 | -3.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.4934 | 2.25 | 1.2899 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | 49.78% | 93.75% | 53.7458% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-13 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OGEN
2026-02-11 16:27:37
Oragenics, Inc. is advancing ONP-002, an intranasal neurosteroid, as the first potential pharmacological treatment for concussion and mild traumatic brain injury (mTBI), targeting a projected $9 billion global market. The company has completed preparations for a Phase 2a clinical trial in Australia, despite minor delays due to health-system consolidation, and outlined key milestones for 2026 including first patient dosing and interim data readouts. ONP-002, with its rapid brain delivery system, aims to address a significant unmet medical need, as mTBI affects millions annually with no FDA-approved therapeutic.
2026-02-09 16:57:58
Oragenics, Inc. is advancing its lead candidate ONP-002, an intranasal neurosteroid, through clinical studies as a potential first pharmacological treatment for concussion and mild traumatic brain injury (mTBI), targeting a projected $9 billion global market. The company is prepared to initiate a Phase 2 clinical trial in Australia, despite delays due to hospital consolidations, and aims for an FDA IND submission for U.S. trials. ONP-002's intranasal delivery system is designed for rapid brain delivery to address inflammation and neuronal damage, addressing a significant unmet medical need.
2026-02-09 13:30:06
Oragenics, Inc. is advancing its lead candidate ONP-002, an intranasal neurosteroid, as a potential first pharmacological treatment for concussion and mild traumatic brain injury (mTBI), targeting a projected $9 billion global market. The company achieved key strategic milestones in 2025, securing clinical infrastructure for a Phase 2 clinical trial in Australia, despite some delays due to hospital consolidations. Oragenics plans to initiate patient dosing, provide interim data throughout 2026, and submit an FDA IND application for U.S. trials, backed by strong financial positioning and no debt.
2026-02-09 13:29:27
Oragenics, Inc. is advancing ONP-002, a novel intranasal neurosteroid, through clinical studies as a potential first pharmacological treatment for concussion and mild traumatic brain injury (mTBI), targeting a projected $9 billion global market. The company has secured clinical infrastructure for a Phase 2 trial in Australia and has demonstrated financial discipline with a clean balance sheet and fully funded Phase 2a trial. Despite a delay in site activation due to hospital consolidations in Australia, Oragenics anticipates near-term patient dosing and expects interim data throughout 2026, with a final readout in Q4 2026.
2026-02-04 13:29:08
Oragenics (OGEN) has partnered with Duck Flats Pharma to prepare for FDA Investigational New Drug (IND) readiness and regulatory execution. This collaboration aims to support the design of its clinical trial for a novel intranasal concussion therapy as it moves towards U.S.-based development, aligning a forthcoming Australian Phase 2a clinical trial with its U.S. regulatory strategy.
2026-02-03 16:30:07
Oragenics, a clinical-stage biotechnology company, has partnered with DUCK FLATS Pharma to advance its novel intranasal concussion therapy (ONP-002) toward U.S. FDA Investigational New Drug (IND) readiness and clinical trial design. This collaboration aims to ensure regulatory diligence and trial integrity, aligning the Company’s upcoming Phase 2a clinical trial in Australia with its U.S. regulatory strategy for a potential first-in-class treatment for concussion and mild traumatic brain injury, an area with no approved therapies. The partnership leverages DUCK FLATS Pharma's extensive experience in drug development and regulatory submissions for intranasal therapies.
